Éric Raymond
Impact in
- Hepatology top 0.2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
Papers in
- Oncology 103
- Cancer Treatment and Pharmacology 28
- Colorectal Cancer Treatments and Studies 24
- Hepatology 29
- Hepatocellular Carcinoma Treatment and Prognosis 29
- Co-authors
- Sandrine J. Faivre (178 shared papers)Esteban Cvitkovic (37 shared papers)Stephen G. Chaney (4 shared papers)Guido Kroemer (2 shared papers)Jan Michał WOYNAROWSKI (4 shared papers)Annemilaï Tijeras‐Raballand (26 shared papers)Armand D.E. Gramont (29 shared papers)Jean‐Pierre Armand (31 shared papers)
- Journals
- Annals of Oncology (35 papers)European Journal of Cancer (32 papers)Targeted Oncology (18 papers)Journal of Clinical Oncology (16 papers)British Journal of Cancer (13 papers)
- Partner nations
- FranceUnited StatesUnited Kingdom
In The Last Decade
Éric Raymond
351 papers receiving 24.9k citations
Éric Raymond's Hit Papers
Peers
Comparison fields: 5 of 158
- Hepatology 2.9k
- Oncology 5.5k
- Epidemiology 3.9k
- Genetics 934
- Pulmonary and Respiratory Medicine 2.8k
Countries citing papers authored by Éric Raymond
This map shows the geographic impact of Éric Raymond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Raymond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Raymond more than expected).
Fields of papers citing papers by Éric Raymond
This network shows the impact of papers produced by Éric Raymond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Raymond. The network helps show where Éric Raymond may publish in the future.
Co-authors
The 25 scholars most cited alongside Éric Raymond, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 361 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors Hit paper breakdown → | 2011 | 2044 |
| 2 | EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer Hit paper breakdown → | 2012 | 1355 |
| 3 | Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer Hit paper breakdown → | 2005 | 1018 |
| 4 | Current development of mTOR inhibitors as anticancer agents Hit paper breakdown → | 2006 | 838 |
| 5 | Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types Hit paper breakdown → | 2002 | 729 |
| 6 | Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial Hit paper breakdown → | 2013 | 670 |
| 7 | Molecular basis for sunitinib efficacy and future clinical development Hit paper breakdown → | 2007 | 601 |
| 8 | 1998 | 553 | |
| 9 | 2005 | 543 | |
| 10 | Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids Hit paper breakdown → | 2015 | 521 |
| 11 | Targeting the TGFβ pathway for cancer therapy Hit paper breakdown → | 2014 | 516 |
| 12 | Oxaliplatin: mechanism of action and antineoplastic activity. | 1998 | 463 |
| 13 | ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas Hit paper breakdown → | 2016 | 459 |
| 14 | 2004 | 432 | |
| 15 | 2008 | 416 | |
| 16 | Cellular and molecular pharmacology of oxaliplatin. | 2002 | 407 |
| 17 | 2000 | 348 | |
| 18 | Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. | 1999 | 340 |
| 19 | 1997 | 325 | |
| 20 | 2000 | 271 |
About Éric Raymond
Éric Raymond is a scholar working on Oncology, Hepatology, Molecular Biology, Epidemiology and Otorhinolaryngology, having authored 361 papers that have together received 25.7k indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (51 papers), Cancer therapeutics and mechanisms (43 papers), Hepatocellular Carcinoma Treatment and Prognosis (29 papers), Cancer Treatment and Pharmacology (28 papers), PI3K/AKT/mTOR signaling in cancer (26 papers), Colorectal Cancer Treatments and Studies (24 papers), Head and Neck Cancer Studies (14 papers) and Lung Cancer Treatments and Mutations (13 papers). The work is most often cited by research in Hepatology (2.9k citations), Oncology (5.5k citations), Epidemiology (3.9k citations), Genetics (934 citations) and Pulmonary and Respiratory Medicine (2.8k citations). Éric Raymond has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Sandrine J. Faivre, Esteban Cvitkovic, Stephen G. Chaney, Guido Kroemer, Jan Michał WOYNAROWSKI, Annemilaï Tijeras‐Raballand, Armand D.E. Gramont, Jean‐Pierre Armand, Cindy Neuzillet and Christophe Le Tourneau. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Targeted Oncology, Journal of Clinical Oncology and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.